Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 15, 2019 - Issue 3
Submit an article Journal homepage
927
Views
1
CrossRef citations to date
0
Altmetric
Reply Letter

Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”

Matt WassermanHealth Economics and Outcomes Research, Pfizer Inc, New York, NY, USACorrespondence[email protected]
,
Maria Gabriela PalaciosMedical and Scientific Affairs, Pfizer Inc., Mexico City, Mexico
,
Ana Gabriela GrajalesMedical and Scientific Affairs, Pfizer Inc., Mexico City, Mexico
,
Michele WilsonRTI Health Solutions, Research Triangle Park, NC, USA
,
Cheryl McDadeRTI Health Solutions, Research Triangle Park, NC, USA
&
Raymond FarkouhHealth Economics and Outcomes Research, Pfizer Inc, Collegeville, PA, USA
Pages 572-574 | Received 03 Dec 2018, Accepted 03 Dec 2018, Published online: 18 Jan 2019

References

  • Wasserman M, Palacios MG, Grajales AG, Baez/Revueltas FB, Wilson M, McDade C, Farkouh R. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Hum Vaccin Immunother. 2018:1–10. doi:10.1080/21645515.2018.1516491.
  • McGirr A, Iqbal SM, Olbrecht J, Varghese L. Comment on:‘clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada’, Wilson et al., 22 June 2018. Infect diseases and therapy. 2018;7(4):535–538.
  • Wilson MR, Wasserman M, Jadavji T, Postma M, Breton M-C, Peloquin F, Stephanie RE, Cheryl MD, Heather LS, Raymond F. Response to McGirr et al.’s comment on “Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada”. Infectious diseases and therapy 7, no. 4 (2018): 539–543.
  • Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert -R-R, Jodar L. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Rev Vaccines. 2017;16(10):1007–1027. doi:10.1080/14760584.2017.1362339.
  • Rinta-Kokko H, Palmu AA, Auranen K, Nuorti JP, Toropainen M, Siira L, Virtanen MJ, Nohynek H, Jokinen J. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland. Vaccine. 2018;36(15):1934–1940. doi:10.1016/j.vaccine.2018.03.001.
  • SIREVA II IR. Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasores. Washington (DC): OPS; 2013.
  • Desmet S, Verhaegen J, Van Ranst M, Peetermans W, Lagrou K. 2018. Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach? Lancet Infect Dis. 18:830–831. doi:10.1016/S1473-3099(18)30346-3.
  • Sings HL, De Wals P, Gessner BD, Isturiz R, Laferriere C, McLaughlin JM, Pelton S, Schmitt H-J, Suaya JA, Jodar L. Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: A systematic review and meta-analysis of observational studies. Clin Infect Dis. 2018; doi: 10.1093/cid/ciy920.
  • Wilson M, Wasserman M, Jadavi T, Postma M, Breton M-C, Peloquin F, et al. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018.
  • de Oliveira LH, Camacho LAB, Coutinho ES, Martinez-Silveira MS, Carvalho AF, Ruiz-Matus C, Toscano CM, Borrow R. Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American countries: a systematic review. PLoS One. 2016;11(12):e0166736. doi:10.1371/journal.pone.0166736.
  • (SAGE) WSAGoEoI. Position paper on pneumococcal vaccines. http://www.who.int/immunization/documents/positionpapers/en/.
  • Sings HL ea. Head-to-head studies on the immune response of the 13-valent (PCV13) and the 10-valent (PCV10) Pneumococcal COnjugate Vaccine in infants. ECCMID. 2017 April 25; Vienna (Austria).
  • van Hoek AJ, Choi YH, Trotter C, Miller E, Jit M. The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine. 2012;30(50):7205–7213. doi:10.1016/j.vaccine.2012.10.017.
  • Thorrington D, van Rossum L, Knol M, de Melker H, Rümke H, Hak E, van Hoek AJ, Arez AP. Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands. PLoS One. 2018;13(2):e0192640. doi:10.1371/journal.pone.0192640.
  • Wasserman M, Lucas A, Jones D, Wilson M, Hilton B, Vyse A, Madhava H, Brogan A, Slack M, Farkouh R. Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK. Epidemiol Infect. 2018;146(14):1797–1806. doi:10.1017/S095026881800198X.
  • Thorrington D, Andrews N, Stowe J, Miller E, van Hoek AJ. Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control. BMC Med. 2018;16(1):13. doi:10.1186/s12916-018-1004-z.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.